Navigation Links
iPierian Appoints Dr. Matthew J. Plunkett as Chief Financial Officer
Date:9/1/2009

SOUTH SAN FRANCISCO, Calif., Sept. 1 /PRNewswire/ -- iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced the appointment of Matthew J. Plunkett, Ph.D., as vice president and chief financial officer.

"Capital formation is critical to our long term success, and Matt's career over the last decade has given him the experience and network to help position iPierian with the investor community," said John P. Walker, chief executive officer of iPierian. "In addition, his scientific background will enable him to articulate the truly unique contribution of cellular reprogramming in shaping the future of drug discovery and development."

Prior to joining iPierian, Dr. Plunkett spent nine years at Oppenheimer & Co., most recently as Managing Director where he lead the firm's biotechnology investment banking practice for the West Coast. His investment banking experience includes over 60 completed biopharmaceutical transactions, including initial public offerings, follow-on offerings, convertible debt, private placements, M&A and financial advisory assignments. Previously, he worked as a research scientist at Sunesis Pharmaceuticals and at Axys Advanced Technologies. He received a Ph.D. in Organic Chemistry from the University of California, Berkeley, where he worked in the lab of Dr. Jonathan Ellman to develop synthetic methodology for the synthesis of structurally diverse small-molecule combinatorial libraries for drug discovery and lead optimization. He received a B.S. with honors in Chemistry, with a History concentration, from Harvey Mudd College.

About iPierian

iPierian is a South San Francisco-based biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new th
'/>"/>

SOURCE iPierian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately held ... tissue reconstruction segment, announced the worldwide launch of ... the shoulder and extremities. The SureLock System provides ... method. The unique delivery eliminates manual tensioning that ... anchor displacement (also commonly know as anchor “creep”). ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Pa., Feb. 23 Endo Pharmaceuticals (Nasdaq: ENDP ... by its wholly owned subsidiary, BTB Purchaser Inc., for all ... Inc. (Nasdaq: IDEV ). American Stock Transfer & ... Endo that, as of 5:00 p.m., New York City time, ...
... Calif., Feb. 23 WaferGen Biosystems,Inc. (OTC ... state-of-the-art gene,expression, genotyping, cell biology and stem ... results of the company,s SmartChip Real-Time PCR,System ... 16th,International Molecular Medicine Tri-Conference. The data ...
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced that Dr. ... as of February 18, 2009. As a result of ... nine members.Dr. Dhingra has been active in oncology clinical ...
Cached Biology Technology:Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period 2Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period 3Data on WaferGen's SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference 2Data on WaferGen's SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference 3Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 2Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 3Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 4Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 5
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
(Date:7/10/2014)... 2014  Aware, Inc. (NASDAQ: AWRE ), ... announced on June 26, 2014 that its Board of ... per share, or approximately $40 million in total.  The ... and a payment date of July 24, 2014.  The ... set an ex-dividend date for this special cash dividend. ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... Researchers at the Buck Institute for Age Research ... to treat rodents afflicted with Parkinson,s Disease (PD). ... same group had previously developed, can be used to ... disease and paves the way for the use of ...
... AUGUSTA, Ga. Children at risk for diabetes before they ... bones, Medical College of Georgia researchers report. A study ... exercise found that the 30 percent with signs of poor ... measure of bone strength, said Dr. Norman Pollock, bone biologist ...
... that RNA plays a major role in cell biology, ranging ... as an important tool in functional genomics. Now WIREs RNA, ... providing RNA experts and researchers not only with a title ... to generate new insights and applications. "In the 10 ...
Cached Biology News:Scientists successfully use human induced pluripotent stem cells to treat Parkinson's in rodents 2Diabetes risk in children increases risk for weak bones 2
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
... tested through 63 ligand ... spanning a broad therapeutic ... includes many non human ... non-selective assays. Used ...
... Receptor (PR) Competitor Assay Kits are ... progesterone receptor binding compounds using fluorescence ... a fusion of glutathione transferase to ... progesterone receptor [PR-LBD(GST)] and a proprietary, ...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Biology Products: